Estrella Immunopharma, Inc. (ESLA)
| Market Cap | 53.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.82M |
| Shares Out | 36.18M |
| EPS (ttm) | -0.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 642,956 |
| Open | 1.690 |
| Previous Close | 1.490 |
| Day's Range | 1.430 - 1.780 |
| 52-Week Range | 0.630 - 3.230 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 16.00 (+981.08%) |
| Earnings Date | Mar 4, 2025 |
About ESLA
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ESLA stock is "Strong Buy" and the 12-month stock price forecast is $16.0.
News
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19-targeted ARTEMIS® T-cel...
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEM...
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEM...
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) ("Estrella", “Estrella Immunopharma”, or the "Company"), a clinical stage biopharmaceutical company focused on de...
TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination
Estrella to Begin Trading on NASDAQ Under the Ticker Symbols "ESLA" and "ESLAW" Beginning October 2, 2023 NEW YORK , Sept. 29, 2023 /PRNewswire/ -- Estrella Immunopharma, Inc., formerly known as Trade...
Estrella Immunopharma Nears Completion Of SPAC Listing
Estrella Immunopharma is nearing completion of its New York listing using a SPAC backed by China's UP Fintech. The cancer therapy developer was only founded last year but thinks it can start generatin...
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
NEW YORK , Sept. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ: UPTD) today announced that, in order to extend the date by which the Company must complete its...
Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Estrella Biopharma, Inc. ("Estrella"), a preclinical-stage biopharmaceutical company focusing on cancer therapeutics, and TradeUP Acquisition Corp. ("TradeUP") (...